{"id":"W4306774464","doi":"10.1016/j.ymthe.2022.09.020","title":"First conditional marketing authorization approval in the European Union for hemophilia “A” gene therapy","year":2022,"lang":"en","type":"editorial","venue":"Molecular Therapy","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":31,"is_retracted":false,"has_abstract":false,"ca_institutions":"Canadian Hemophilia Society","funders":"","keywords":"Factor IX; Medicine; Haemophilia; Genetic enhancement; Clotting factor; Haemophilia B; Haemophilia A; Marketing authorization; Coagulation; Internal medicine; Pediatrics; Bioinformatics; Gene; Genetics; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00752267,0.0005283816,0.0003440954,0.0001966697,0.0004605829,0.0001401661,0.001313772,0.0004766358,0.0001270311],"category_scores_gemma":[0.000361323,0.0004633368,0.0003679489,0.0003444245,0.0001273729,0.000006851195,0.0001580781,0.0007480987,0.000007758485],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001050432,"about_ca_system_score_gemma":0.0003741176,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001764884,"about_ca_topic_score_gemma":0.00003407584,"domain_scores_codex":[0.9925256,0.004249844,0.000483775,0.001040056,0.001104136,0.0005965292],"domain_scores_gemma":[0.9981411,0.0002994258,0.0002622769,0.0009696324,0.0002519087,0.00007571957],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","study_design_scores_codex":[0.007609757,0.0005331011,0.00002599014,0.00007736742,0.0004304479,0.0000757435,0.0002898785,0.001781423,0.5015891,0.00005861906,0.4644929,0.02303565],"study_design_scores_gemma":[0.003603731,0.002746354,0.0000755515,0.00001816581,0.00001159703,0.000006629708,0.00005321017,0.00008704849,0.04448296,0.0002872052,0.9480872,0.0005403939],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"editorial","genre_gemma":"editorial","genre_scores_codex":[0.3748231,0.04351695,0.05067841,0.006112129,0.4972582,0.01806976,0.005195249,0.0002884391,0.004057834],"genre_scores_gemma":[0.1483241,0.02121297,0.001222547,0.002275161,0.7282848,0.004118829,0.09086984,0.001202009,0.002489788],"genre_candidate":"editorial","genre_consensus":"editorial","teacher_disagreement_score":0.4835942,"threshold_uncertainty_score":0.9997818,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01582316216343343,"score_gpt":0.2883382761039605,"score_spread":0.272515113940527,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}